Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma

被引：0

作者：

Goto, Hideki ^{[1
,2
]}

Sawa, Masashi ^{[3
]}

Fujiwara, Shin-ichiro ^{[4
]}

Ri, Masaki ^{[5
]}

Ishida, Tadao ^{[6
]}

Takeuchi, Masahiro ^{[7
]}

Ishitsuka, Kenji ^{[8
]}

Toyosaki, Masako ^{[9
]}

Sunami, Kazutaka ^{[10
]}

Tsukada, Junichi ^{[11
]}

Sonoki, Takashi ^{[12
]}

Shimogomi, Aiko ^{[13
]}

Ichihashi, Yuki ^{[13
]}

Ouchi, Yoshiumi ^{[13
]}

Miyamoto, Toshihiro ^{[14
]}

Hino, Masayuki ^{[15
]}

Maeda, Yoshinobu ^{[16
]}

Teshima, Takanori ^{[1
,2
]}

机构：

[1] Hokkaido Univ, Grad Sch Med, Dept Hematol, Fac Med, Sapporo, Japan

[2] Hokkaido Univ Hosp, Div Lab & Transfus Med, Sapporo, Japan

[3] Anjo Kosei Hosp, Dept Hematol & Oncol, Anjo, Japan

[4] Jichi Med Univ, Dept Med, Div Hematol, Shimotsuke, Japan

[5] Nagoya City Univ, Grad Sch Med Sci, Dept Hematol & Oncol, Nagoya, Japan

[6] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[7] Chiba Canc Ctr, Div Hematol Oncol, Chiba, Japan

[8] Kagoshima Univ, Dept Hematol & Rheumatol, Kagoshima, Japan

[9] Tokai Univ, Sch Med, Dept Hematol & Oncol, Isehara, Japan

[10] NHO Okayama Med Ctr, Dept Hematol, Okayama, Japan

[11] Univ Occupat & Environm Hlth, Dept Hematol, Kitakyushu, Japan

[12] Wakayama Med Univ, Dept Hematol Oncol, Wakayama, Japan

[13] Kyowa Kirin Co Ltd, Tokyo, Japan

[14] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Dept Hematol, Kanazawa, Japan

[15] Osaka Metropolitan Univ, Grad Sch Med, Dept Hematol, Osaka, Japan

[16] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Hematol & Oncol, Okayama, Japan

来源：

SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期

关键词：

Multiple myeloma; Pegfilgrastim; Lymphoma; CD34; Mobilization; Peripheral blood stem cell; AUTOLOGOUS HEMATOPOIETIC STEM; COLONY-STIMULATING FACTOR; POOR MOBILIZATION; AMERICAN SOCIETY; TRANSPLANTATION; CHEMOTHERAPY; FILGRASTIM; LEUKAPHERESIS; ENGRAFTMENT; STRATEGIES;

D O I：

10.1038/s41598-025-98453-7

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or malignant lymphoma (ML). Efficacy and safety, along with CD34-positive cell mobilization outcomes were assessed in patients with MM, who were randomly assigned to pegfilgrastim (n = 30) or daily filgrastim (n = 31), and ML (pegfilgrastim only, n = 13) cohorts. In the MM cohort, CD34-positive cell counts >= 2 x 106/kg were achieved in 100% of patients in the pegfilgrastim group and 96.7% in the filgrastim group (difference: 3.3%; 80% confidence interval: -0.9-7.5%), demonstrating the non-inferiority of pegfilgrastim to filgrastim. All patients in the ML cohort achieved >= 2 x 106/kg CD34-positive cell counts. The plerixafor administration rates in the MM cohort were 50.0% and 63.3% in the pegfilgrastim and filgrastim groups, respectively, and 91.7% in the ML cohort. There were no major differences in safety measures between the two groups. Although the sample size was small, particularly in the ML cohort, a single dose of pegfilgrastim demonstrated comparable efficacy and safety to daily doses of filgrastim, indicating its potential for clinical use while reducing patient burden.Trial Registration: jRCT2011210029, NCT05007652.

引用

页数：12

共 45 条

[1] A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor [J].